Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Machine, Furnitures, Fixtures & OtherOther Gross PP&E Adjustments
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation & Amortization: 2015-2022

  • Spyre Therapeutics' Accumulated Depreciation & Amortization rose 47.89% to $4.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $10.0 million, marking a year-over-year increase of 51.46%. This contributed to the annual value of $744,000 for FY2023, which is 52.52% down from last year.
  • Spyre Therapeutics' Accumulated Depreciation & Amortization amounted to $4.1 million in Q4 2022, which was up 47.89% from $2.8 million recorded in Q4 2021.
  • Over the past 5 years, Spyre Therapeutics' Accumulated Depreciation & Amortization peaked at $4.1 million during Q4 2022, and registered a low of $752,000 during Q4 2018.
  • For the 3-year period, Spyre Therapeutics' Accumulated Depreciation & Amortization averaged around $3.0 million, with its median value being $2.8 million (2021).
  • Data for Spyre Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY soared of 87.96% (in 2020) over the last 5 years.
  • Spyre Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $752,000 in 2018, then soared by 40.29% to $1.1 million in 2019, then surged by 87.96% to $2.0 million in 2020, then surged by 41.30% to $2.8 million in 2021, then soared by 47.89% to $4.1 million in 2022.
  • Its last three reported values are $4.1 million in Q4 2022, $2.8 million for Q4 2021, and $2.0 million during Q4 2020.